Madrigal Pharmaceuticals Inc (MDGL)
283.69
-18.98
(-6.27%)
USD |
NASDAQ |
Nov 15, 10:54
Madrigal Pharmaceuticals Net Income (TTM): -518.67M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | -518.67M |
| June 30, 2024 | -510.45M |
| March 31, 2024 | -444.28M |
| December 31, 2023 | -373.63M |
| September 30, 2023 | -347.34M |
| June 30, 2023 | -329.80M |
| March 31, 2023 | -314.73M |
| December 31, 2022 | -295.35M |
| September 30, 2022 | -273.99M |
| June 30, 2022 | -255.90M |
| March 31, 2022 | -246.82M |
| December 31, 2021 | -241.85M |
| September 30, 2021 | -236.42M |
| June 30, 2021 | -231.28M |
| March 31, 2021 | -218.66M |
| December 31, 2020 | -202.24M |
| September 30, 2020 | -170.86M |
| June 30, 2020 | -134.33M |
| March 31, 2020 | -105.00M |
| December 31, 2019 | -83.95M |
| September 30, 2019 | -67.68M |
| June 30, 2019 | -54.77M |
| March 31, 2019 | -41.53M |
| December 31, 2018 | -32.81M |
| September 30, 2018 | -29.78M |
| Date | Value |
|---|---|
| June 30, 2018 | -29.63M |
| March 31, 2018 | -31.52M |
| December 31, 2017 | -31.15M |
| September 30, 2017 | -30.46M |
| June 30, 2017 | -36.14M |
| March 31, 2017 | -30.67M |
| December 31, 2016 | -26.39M |
| September 30, 2016 | -20.52M |
| June 30, 2016 | -8.273M |
| March 31, 2016 | -25.20M |
| December 31, 2015 | -44.19M |
| September 30, 2015 | -62.66M |
| June 30, 2015 | -80.82M |
| March 31, 2015 | -83.31M |
| December 31, 2014 | -86.16M |
| September 30, 2014 | -89.97M |
| June 30, 2014 | -92.52M |
| March 31, 2014 | -93.02M |
| December 31, 2013 | -90.19M |
| September 30, 2013 | -84.15M |
| June 30, 2013 | -76.63M |
| March 31, 2013 | -68.47M |
| December 31, 2012 | -62.79M |
| September 30, 2012 | -55.41M |
| June 30, 2012 | -53.15M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-518.67M
Minimum
Sep 2024
-83.95M
Maximum
Dec 2019
-276.78M
Average
-251.36M
Median
Net Income (TTM) Benchmarks
| ADMA Biologics Inc | 68.13M |
| 89bio Inc | -288.96M |
| Corcept Therapeutics Inc | 141.82M |
| Sarepta Therapeutics Inc | 121.84M |
| Matinas BioPharma Holdings Inc | -22.91M |